Table 3.
Univariate analyses for DFS and OS of GC patients
| Variables | n | Disease-free survival | Overall survival | ||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | ||
| Overall | 1915 | ||||||
| Sex | |||||||
| Male | 1333 | Ref. | Ref. | ||||
| Female | 582 | 0.93 | 0.77–1.11 | 0.400 | 0.87 | 0.72–1.06 | 0.161 |
| Age (years) | |||||||
| < 58 | 995 | Ref. | Ref. | ||||
| ≥ 58 | 920 | 1.40 | 1.19–1.65 | < 0.001 | 1.65 | 1.39–1.96 | < 0.001 |
| Tumor location | |||||||
| GEJ + Upper 1/3 | 499 | Ref. | Ref. | ||||
| Middle 1/3 | 468 | 0.82 | 0.66–1.01 | 0.063 | 0.81 | 0.65–1.00 | 0.053 |
| Lower 1/3 | 948 | 0.54 | 0.44–0.66 | < 0.001 | 0.55 | 0.45–0.67 | < 0.001 |
| Tumor size | |||||||
| < 3.2 cm | 967 | Ref. | Ref. | ||||
| ≥ 3.2 cm | 948 | 2.93 | 2.45–3.51 | < 0.001 | 3.05 | 2.53–3.68 | < 0.001 |
| Histologic grade | |||||||
| Well-moderately | 354 | Ref. | Ref. | ||||
| Poorly | 1516 | 1.62 | 1.27–2.06 | < 0.001 | 1.51 | 1.19–1.92 | < 0.001 |
| T category | |||||||
| T1 | 523 | Ref. | Ref. | ||||
| T2 | 266 | 2.49 | 1.53–4.06 | < 0.001 | 2.62 | 1.56–4.41 | < 0.001 |
| T3 | 201 | 5.68 | 3.60–8.95 | < 0.001 | 6.11 | 3.77–9.92 | < 0.001 |
| T4a | 889 | 11.93 | 8.18–17.38 | < 0.001 | 13.05 | 8.71–19.56 | < 0.001 |
| T4b | 36 | 22.94 | 13.34–39.45 | < 0.001 | 28.20 | 15.97–49.77 | < 0.001 |
| N category | |||||||
| N0 | 806 | Ref. | Ref. | ||||
| N1 | 344 | 2.49 | 1.81–3.43 | < 0.001 | 2.68 | 1.94–3.71 | < 0.001 |
| N2 | 330 | 5.23 | 3.95–6.94 | < 0.001 | 5.08 | 3.79–6.82 | < 0.001 |
| N3a | 333 | 10.23 | 7.86–13.32 | < 0.001 | 10.34 | 7.87–13.58 | < 0.001 |
| N3b | 102 | 16.90 | 12.30–23.22 | < 0.001 | 18.88 | 13.61–26.20 | < 0.001 |
| VELIPI | |||||||
| Negative | 1050 | Ref. | Ref. | ||||
| Positive | 865 | 3.72 | 3.10–4.46 | < 0.001 | 3.43 | 2.86–4.12 | < 0.001 |
| No. of retrieved LNs | |||||||
| < 15 | 367 | Ref. | Ref. | ||||
| ≥ 15 | 1548 | 1.22 | 0.98–1.51 | 0.078 | 1.17 | 0.93–1.45 | 0.175 |
| Adjuvant treatment | |||||||
| No | 539 | Ref. | Ref. | ||||
| Single drug | 344 | 1.57 | 1.17–2.11 | 0.003 | 1.54 | 1.13–2.10 | 0.006 |
| Double drugs | 688 | 2.13 | 1.66–2.71 | < 0.001 | 2.27 | 1.76–2.92 | < 0.001 |
| Triple drugs | 210 | 3.24 | 2.44–4.31 | < 0.001 | 2.98 | 2.21–4.02 | < 0.001 |
| CRT | 134 | 3.79 | 2.77–5.20 | < 0.001 | 3.58 | 2.58–4.97 | < 0.001 |
| TD | |||||||
| Absent | 1714 | Ref. | Ref. | ||||
| Present | 201 | 4.14 | 3.42–5.02 | < 0.001 | 4.45 | 3.66–5.42 | < 0.001 |
Abbreviations: CI confidence interval, DFS disease-free survival, GC gastric cancer, GEJ, gastroesophageal junction, HR hazard ratio, LNs lymph nodes, OS overall survival, PSM propensity score matching, Ref. reference, TD tumor deposit, VELIPI vascular emboli, lymphatic, and perineural invasion